New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
09:22 EDTEW, COV, STJ, MDT, HTWR, ABTCovidian acquisiton may signal increased sector M&A, says CRT Capital
CRT Capital believes Medtronic's (MDT) acquisition of Covidien (COV) may signal an increase in sector M&A. The analyst believes potential combinations that make strategic sense are Abbott (ABT) or St. Jude Medical (STJ) for Edwards Lifesciences (EW) or a takeover of HeartWare (HTWR).
News For MDT;COV;ABT;STJ;EW;HTWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
08:03 EDTSTJSt. Jude launches Proclaim Elite in Europe
Subscribe for More Information
07:16 EDTSTJSt. Jude Medical management to meet with Deutsche Bank
Subscribe for More Information
November 27, 2015
06:59 EDTMDTMedtronic volatility flat into Q2 and outlook
Subscribe for More Information
November 24, 2015
08:31 EDTMDTMedtronic remains a top tier performer in Med Device space, says Cowen
Subscribe for More Information
November 20, 2015
05:22 EDTMDTStocks with implied volatility movement; MDT UNH
Stocks with implied volatility movement; Medtronic (MDT) 25, UnitedHealth (UNH) 30 according to iVolatility.
November 19, 2015
16:34 EDTEWEdwards Lifesciences approves two-for-one stock split
Edwards Lifesciences approved a two-for-one split of the company's outstanding shares of common stock to be effected as a 100% stock dividend. This will be the company's second stock split since it went public in April 2000. Stockholders of record at the close of business on November 30 will be issued one additional share of common stock for each share owned as of that date. The additional shares will be distributed on December 11. The stock split will increase the number of common shares outstanding from approximately 108M shares as of the record date, to approximately 216M shares.
08:02 EDTSTJSt. Jude Medical announces FDA approval of Proclaim Elite SCS system
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use